<DOC>
	<DOCNO>NCT01931189</DOCNO>
	<brief_summary>The purpose study assess equivalence pharmacokinetics NI-071 infliximab ( comparator ) Japanese healthy volunteer</brief_summary>
	<brief_title>Pharmacokinetics Study NI-071</brief_title>
	<detailed_description />
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Healthy male subject ( healthy define clinically relevant abnormality identify detailed medical history , clinical laboratory test , etc . ) 2 . Body Mass Index ( BMI ) 18.5 25.0 kg/m2 , total body weight 50 80 kg 1 . Subjects follow past History concomitant diseases Chronic recurrent infectious disease Demyelinating disease Congestive heart failure lymphoproliferative disorder myelodysplastic syndrome Malignancy Interstitial lung disease 2 . Subjects active latent tuberculosis history tuberculosis</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>